FOXO Technologies Inc. (FOXO)

NYSEAMERICAN: FOXO · IEX Real-Time Price · USD
0.365
+0.015 (4.29%)
Mar 28, 2024, 10:04 AM EDT - Market open
4.29%
Market Cap 2.89M
Revenue (ttm) 453,000
Net Income (ttm) -73.13M
Shares Out 8.95M
EPS (ttm) -13.95
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 149,792
Open 0.368
Previous Close 0.350
Day's Range 0.346 - 0.370
52-Week Range 0.250 - 9.300
Beta 1.70
Analysts n/a
Price Target n/a
Earnings Date May 9, 2024

About FOXO

FOXO Technologies Inc. engages in epigenetic biomarker underwriting technology and consumer engagement platform service business in the United States. It operates through two segments, FOXO Labs and FOXO Life. The company applies automated machine learning and artificial intelligence technologies to discover epigenetic biomarkers of human health, wellness, and aging. It offers FOXO Labs, a commercializing proprietary epigenetic biomarker technology enables the adoption of saliva-based health and wellness biomarker solutions for underwriting and... [Read more]

Sector Healthcare
Founded 2019
Employees 4
Stock Exchange NYSEAMERICAN
Ticker Symbol FOXO
Full Company Profile

Financial Performance

In 2022, FOXO's revenue was $511,000, an increase of 325.83% compared to the previous year's $120,000. Losses were -$95.26 million, 147.5% more than in 2021.

Financial Statements

News

FOXO Technologies Announces Non-Binding Agreement for Potentially Transformative Merger with M2i Global

Proposed Combination to Focus on Securing Our Nation's Supply to Critical Materials and Resources Proposed Combination to Focus on Securing Our Nation's Supply to Critical Materials and Resources

6 weeks ago - GlobeNewsWire

FOXO Technologies Announces Appointment of Capital Markets Veteran Francis Colt deWolf to the Board of Directors

MINNEAPOLIS--(BUSINESS WIRE)--FOXO Technologies Inc. (NYSE American: FOXO) (the “Company”), today announced the appointment of Francis Colt deWolf to the Company's Board of Directors. Mr. deWolf III b...

2 months ago - Business Wire

FOXO Technologies Formalizes License Agreement with KR8.ai to Power New Epigenetic Wellness Solutions

MINNEAPOLIS--(BUSINESS WIRE)--FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”), a leader in the field of commercializing epigenetic biomarker technology, today announced it has f...

2 months ago - Business Wire

FOXO Technologies Inc. Announces Receipt of Notice of Non-Compliance with NYSE Continued Listing Requirements

MINNEAPOLIS--(BUSINESS WIRE)--On November 21, 2023, FOXO Technologies Inc., a Delaware corporation (the “Company”), received an official notice of noncompliance (the “NYSE American Notice”) from NYSE ...

3 months ago - Business Wire

FOXO Technologies On Track to Commence Commercial Rollout of VITHAR™ AI Health Coach in Early 2024

MINNEAPOLIS--(BUSINESS WIRE)--FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”), a leader in the field of epigenetic biomarker technology, today provided a business update on the ...

4 months ago - Business Wire

FOXO Technologies Receives Notice from NYSE American Regarding Late Filing of Quarterly Report on Form 10-Q

MINNEAPOLIS--(BUSINESS WIRE)--FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”), a leader in the field of epigenetic biomarker technology, announced that on November 21, 2023, it ...

4 months ago - Business Wire

FOXO Technologies Provides Reminder for Webinar to be Held Today, November 10th at 10 AM Eastern Time, to Unveil VITHAR™ AI Health Coach

MINNEAPOLIS--(BUSINESS WIRE)--FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”), a leader in the field of epigenetic biomarker technology, today provided a reminder that it will h...

4 months ago - Business Wire

FOXO Technologies to Unveil VITHAR™ AI Health Coach; Schedules Webinar for Friday, November 10th at 10 AM Eastern Time

MINNEAPOLIS--(BUSINESS WIRE)--FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”), a leader in the field of epigenetic biomarker technology, today announced that it will host a webi...

5 months ago - Business Wire

FOXO Technologies Expects Class A Common Stock to Resume Trading, Today, November 7, in Connection with 1-for-10 Reverse Stock Split

MINNEAPOLIS--(BUSINESS WIRE)--FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”), a leader in the field of epigenetic biomarker technology, today announced that it expects its Clas...

5 months ago - Business Wire

FOXO Technologies Unveils Plans for New Direct-to Consumer Offering Combining the Company's Epigenetic Data with the Power of AI

MINNEAPOLIS--(BUSINESS WIRE)--FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”), a leader in the field of commercializing epigenetic biomarker technology, today announced plans fo...

5 months ago - Business Wire

FOXO Technologies Inc. Announces Reverse Stock Split

MINNEAPOLIS--(BUSINESS WIRE)--FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”), a leader in the field of commercializing epigenetic biomarker technology, today announced that its...

5 months ago - Business Wire

FOXO Technologies Completes Strategic Alternatives Review and Outlines Latest Progress Executing Corporate Strategy

MINNEAPOLIS--(BUSINESS WIRE)--FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”), a leader in the field of commercializing epigenetic biomarker technology, today announces it has c...

5 months ago - Business Wire

FOXO Technologies Announces Issue Notification from USPTO for a Patent Leveraging Machine Learning Approaches to Enable the Commercialization of Epigenetic Biomarkers

MINNEAPOLIS--(BUSINESS WIRE)--FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”), a leader in the field of commercializing epigenetic biomarker technology, today announced that the...

5 months ago - Business Wire

FOXO Technologies™ Interim CEO Mark White Provides Letter to Shareholders Outlining New AI-Enabled Direct-to-Consumer Strategy and Immediate Expense Reductions

MINNEAPOLIS--(BUSINESS WIRE)--FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”), a leader in the field of commercializing epigenetic biomarker technology, today provided a letter ...

6 months ago - Business Wire

FOXO Technologies Announces Agreement With Atrio Insurance

MINNEAPOLIS, Minn.--(BUSINESS WIRE)--FOXO Technologies Inc.™ (NYSEAM: FOXO), a technology platform company whose products and services seek to address long-standing, core problems within the life insu...

7 months ago - Business Wire

FOXO Technologies Inc. Announces NYSE American Acceptance of Compliance Plan

MINNEAPOLIS--(BUSINESS WIRE)--On August 29, 2023, FOXO Technologies Inc. (the “Company”) (NYSEAM: FOXO) received a letter (the “Letter”) from NYSE American LLC (“NYSE American”) stating that NYSE Amer...

7 months ago - Business Wire

FOXO Technologies Inc. Announces Receipt of Second Notice of Non-Compliance from NYSE American

MINNEAPOLIS--(BUSINESS WIRE)--On August 16, 2023, FOXO Technologies Inc. (NYSEAM: FOXO) (the “Company”) received a second written notice (the “Notice”) from the NYSE American LLC (the “NYSE American”)...

7 months ago - Business Wire

FOXO Technologies™ Collaborates with DataRobot to Pave the Way for AI-Driven Epigenetic Biomarker Research in Human Longevity

MINNEAPOLIS--(BUSINESS WIRE)--FOXO Technologies Inc. (NYSEAM: FOXO), a leader in the field of commercializing epigenetic biomarker technology, has advanced in its mission to utilize the power of epige...

8 months ago - Business Wire

FOXO Technologies™ Announces Second Quarter 2023 Financial Results

MINNEAPOLIS--(BUSINESS WIRE)--FOXO Technologies Inc. (NYSEAM: FOXO), a leader in the field of commercializing epigenetic biomarker technology, today reported financial results for the second quarter e...

8 months ago - Business Wire

FOXO Technologies™ Sets Second Quarter 2023 Business Update Call for Thursday, August 10, 2023 at 3:15 p.m. CT

MINNEAPOLIS--(BUSINESS WIRE)--FOXO Technologies Inc. (NYSE_AM: FOXO), a leader in epigenetic biomarker discovery and commercialization, today announced that it will report financial results for the se...

8 months ago - Business Wire

Longevity Biotech Companies GERO and FOXO Technologies™ to Embark on Joint Initiative on Artificial Intelligence and Epigenetic Data to Discover Signatures of Human Health Trajectories

PALO ALTO, Calif. & MINNEAPOLIS, Minn.--(BUSINESS WIRE)--GERO, a leading AI-driven biotechnology company focused on aging and longevity and FOXO Technologies Inc. (NYSEAM: FOXO), a leader in epigeneti...

8 months ago - Business Wire

FOXO Technologies Launches Bioinformatics Services to Revolutionize Epigenetic Data Analysis

MINNEAPOLIS--(BUSINESS WIRE)--FOXO Technologies Inc.™ (NYSEAM: FOXO), a leader in the field of commercializing epigenetic biomarker technology, today announced the launch of its cutting-edge Bioinform...

9 months ago - Business Wire

FOXO Technologies Announces Results of Annual Stockholders Meeting

MINNEAPOLIS--(BUSINESS WIRE)--FOXO Technologies Inc.™ (NYSEAM: FOXO) ( the “Company”), a leader in commercializing epigenetic biomarkers of health and aging, today announced results of its Annual Meet...

10 months ago - Business Wire

NYSE American Has Commenced Delisting Proceedings in the FOXO WS warrants of FOXO Technologies Inc.

MINNEAPOLIS--(BUSINESS WIRE)--On May 15, 2023 NYSE American LLC (“NYSE American”) provided written notice to FOXO Technologies Inc. (NYSEAM: FOXO) (the “Company” or “FOXO”) that NYSE American had halt...

11 months ago - Business Wire

NYSE American to Commence Delisting Proceedings in Warrants of FOXO Technologies Inc. (FOXO WS) and Suspends Trading Immediately

NEW YORK--(BUSINESS WIRE)--NYSE American LLC (“NYSE American” or the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the warrants of FOXO...

11 months ago - Business Wire